Myriad Genetics (MYGN) Tops Q2 EPS by 2c
Tweet
Share
E-mailGet Alerts MYGN Hot Sheet
Price: $4.63 --0%
Revenue Growth %: -2.7%
Financial Fact:
Interest income: 300K
Today's EPS Names:
DTGI, CRMT, MAYS, More
Revenue Growth %: -2.7%
Financial Fact:
Interest income: 300K
Today's EPS Names:
DTGI, CRMT, MAYS, More
Join SI Premium – FREE
Myriad Genetics (NASDAQ: MYGN) reported Q2 EPS of $0.26, $0.02 better than the analyst estimate of $0.24. Revenue for the quarter came in at $196.5 million versus the consensus estimate of $189.72 million.
GUIDANCE:
Myriad Genetics sees Q3 2017 EPS of $0.23-$0.25, versus the consensus of $0.25.
For earnings history and earnings-related data on Myriad Genetics (MYGN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Myriad Genetics Expands Availability of Precise MRD™ for Colorectal, Renal and Breast Cancers, Supported by New Publication
- Cerebras Systems (CBRS) Misses Q1 EPS, Revenues Beat
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
